or Try an Advanced Search...

    Technical Analysis for ORGS - Orgenesis Inc.

    Grade Last Price % Change Price Change
    B 0.65 8.13% 0.05
    ORGS closed up 8.13 percent on Monday, July 1, 2024, on 1.84 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ORGS trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Calm After Storm Range Contraction 8.13%
    NR7 Range Contraction 8.13%
    Narrow Range Bar Range Contraction 8.13%
    Wide Bands Range Expansion 8.13%
    Gapped Down Weakness 8.13%
    Calm After Storm Range Contraction 2.33%
    Narrow Range Bar Range Contraction 2.33%
    Wide Bands Range Expansion 2.33%
    Older End-of-Day Signals for ORGS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    2x Volume Pace about 10 hours ago
    1.5x Volume Pace about 10 hours ago
    Up 5% about 10 hours ago
    Up 3% about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ORGS Chart by TradingView
    Basic chart:

    Profile

    Orgenesis Inc. Description

    Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Diabetes Clinical Development Stem Cell Cell Therapy Insulin Endocrine System Hormones Regenerative Medicine Contract Manufacturing Peptide Hormones Contract Manufacturing Services Type I Diabetes Assay Development Services Diabetes Mellitus Type 1 Medicinal Product Medicinal Products

    Is ORGS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 6 Orgenesis files to sell 2.48M shares of common stock for holders
    May 21 Orgenesis GAAP EPS of -$0.29, revenue of $0.14M
    May 21 Orgenesis Provides Business Update for the First Quarter of 2024
    Apr 15 Orgenesis Provides Year End Business Update
    Apr 10 Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
    Apr 2 Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Mar 18 Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
    Mar 13 Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
    Mar 4 Orgenesis announces $2.3M private placement
    Mar 4 Orgenesis Inc. Announces $2.3 Million Private Placement
    See more ORGS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.42
    52 Week Low 0.25
    Average Volume 96,945
    200-Day Moving Average 0.57
    50-Day Moving Average 0.53
    20-Day Moving Average 0.55
    10-Day Moving Average 0.58
    Average True Range 0.07
    RSI (14) 60.32
    ADX 20.46
    +DI 28.87
    -DI 12.29
    Chandelier Exit (Long, 3 ATRs) 0.55
    Chandelier Exit (Short, 3 ATRs) 0.66
    Upper Bollinger Bands 0.66
    Lower Bollinger Band 0.43
    Percent B (%b) 0.95
    BandWidth 42.10
    MACD Line 0.03
    MACD Signal Line 0.01
    MACD Histogram 0.0129
    Fundamentals Value
    Market Cap 20.68 Million
    Num Shares 31.9 Million
    EPS -0.91
    Price-to-Earnings (P/E) Ratio -0.71
    Price-to-Sales 0.34
    Price-to-Book 0.77
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.78
    Resistance 3 (R3) 0.78 0.74 0.76
    Resistance 2 (R2) 0.74 0.70 0.74 0.75
    Resistance 1 (R1) 0.69 0.68 0.71 0.69 0.75
    Pivot Point 0.65 0.65 0.66 0.65 0.65
    Support 1 (S1) 0.60 0.61 0.62 0.60 0.55
    Support 2 (S2) 0.56 0.59 0.56 0.54
    Support 3 (S3) 0.51 0.56 0.54
    Support 4 (S4) 0.51